Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment
Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment
Recommend0 recommendationsPublished in US National Health Agency Sources
Related Articles
Drug Overdose Deaths During COVID-19: A Historical Spike Among Latinos?
More Americans have died from a drug overdose in the last 12 months than at any other point in history. New research has found a historical 21% spike in drug overdose deaths amid COVID-19. This data comes during a pandemic that has disproportionately affected Latinos — moreover, it’s worsening already harsh historical inequities this group …
The post Drug Overdose Deaths During COVID-19: A Historical Spike Among Latinos? appeared first on Salud America.
FDA Approves New Drug for Alzheimer’s, But Scientists Divided Over Decision
The U.S. Food and Drug Administration approved a new drug called Aduhelm (aducanumab) to treat Alzheimer’s disease, the most common form of dementia. Many are applauding the drug and are encouraged by the scientific progress in a field that has long had limited treatment options. Alzheimer’s affects over 6.2 million people in the U.S., with …
The post FDA Approves New Drug for Alzheimer’s, But Scientists Divided Over Decision appeared first on Salud America.
In a Nation Growing Hostile Toward Drugs and Homelessness, Los Angeles Tries Leniency
LOS ANGELES — Inside a bright new building in the heart of Skid Row, homeless people hung out in a canopy-covered courtyard — some waiting…
Breaking Down Why Medicare Part D Premiums Are Likely To Go Up
Medicare enrollees who buy the optional Part D drug benefit may see substantial premium price hikes — potentially up to $50 a month — when…
Top California Democrats Clash Over How To Rein In Drug Industry Middlemen
California Gov. Gavin Newsom and state legislators in Sacramento seem to agree: Prescription drug prices are too high. But lawmakers and the second-term governor are…
